Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to “Hold” at Zacks Research

Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by investment analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report issued on Tuesday, Zacks reports.

Other equities analysts have also issued reports about the company. Piper Sandler initiated coverage on Supernus Pharmaceuticals in a research report on Wednesday. They issued an “overweight” rating and a $47.00 target price on the stock. Weiss Ratings downgraded shares of Supernus Pharmaceuticals from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Friday, October 30th. Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Cantor Fitzgerald lifted their price target on shares of Supernus Pharmaceuticals from $67.00 to $87.00 and gave the stock an “overweight” rating in a research note on Wednesday. Finally, Jefferies Financial Group initiated coverage on shares of Supernus Pharmaceuticals in a report on Wednesday. They issued a “strong-buy” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Supernus Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $63.50.

Supernus Pharmaceuticals Stock Performance

Shares of NASDAQ SUPN opened at $28.21 on Tuesday. Supernus Pharmaceuticals has a 1 year low of $26.74 and a 1 year high of $42.81. The stock’s 50-day simple moving average is $41.74 and its 200-day simple moving average is $47.04. The firm has a market cap of $3.33 billion, a price-to-earnings ratio of 7.88 and a beta of 0.84.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Thursday, October 29th. The specialty pharmaceutical company reported $0.35 EPS for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.14). Supernus Pharmaceuticals had a net margin of 32.75% and a negative return on equity of 418.04%. The business had revenue of $208.60 million during the quarter, compared to analysts’ expectations of $217.56 million. During the same period in the prior year, the company posted ($0.80) EPS. The company’s revenue for the quarter was up 18.0% on a year-over-year basis. As a group, research analysts predict that Supernus Pharmaceuticals will post 3.66 EPS for the current year.

Institutional Trading of Supernus Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Summit Global Investments lifted its holdings in Supernus Pharmaceuticals by 6.1% during the 1st quarter. Summit Global Investments now owns 4,436 shares of the specialty pharmaceutical company’s stock worth $229,000 after buying an additional 256 shares during the last quarter. PNC Financial Services Group Inc. grew its position in shares of Supernus Pharmaceuticals by 2.3% in the 1st quarter. PNC Financial Services Group Inc. now owns 14,548 shares of the specialty pharmaceutical company’s stock worth $752,000 after acquiring an additional 321 shares in the last quarter. Corient Private Wealth LP grew its position in shares of Supernus Pharmaceuticals by 6.6% in the 2nd quarter. Corient Private Wealth LP now owns 5,163 shares of the specialty pharmaceutical company’s stock worth $240,000 after acquiring an additional 321 shares in the last quarter. Juncture Wealth Strategies LLC grew its position in shares of Supernus Pharmaceuticals by 5.8% in the 3rd quarter. Juncture Wealth Strategies LLC now owns 6,778 shares of the specialty pharmaceutical company’s stock worth $292,000 after acquiring an additional 374 shares in the last quarter. Finally, Versant Capital Management Inc increased its holdings in shares of Supernus Pharmaceuticals by 47.2% in the 3rd quarter. Versant Capital Management Inc now owns 1,503 shares of the specialty pharmaceutical company’s stock valued at $65,000 after acquiring an additional 482 shares during the last quarter. 60.33% of the stock is owned by institutional investors.

Key Stories Impacting Supernus Pharmaceuticals

Here are the key news stories impacting Supernus Pharmaceuticals this week:

• Positive Sentiment: Cantor Fitzgerald raised its price target to $87 and maintained an “overweight” rating, signaling substantial potential upside in the firm’s view. However, the target may not reflect the completed merger or subsequent listing changes. Cantor Fitzgerald rating information
• Positive Sentiment: Recent commentary describes SUPN as potentially undervalued, citing ONAPGO’s exclusivity and the combined company’s prospects. These are valuation arguments, not company guidance. Supernus after its Indivior merger looks undervalued Supernus may be undervalued after ONAPGO exclusivity
• Positive Sentiment: One report highlights $473 million in shareholder payouts, a potentially favorable one-time return of capital. Supernus sends $473 million to shareholders
• Neutral Sentiment: Supernus completed its merger with Indivior, creating a CNS-focused biopharmaceutical company. The combination could broaden the business, but investors will assess the merged company’s prospects and integration. Supernus completes merger with Indivior
• Negative Sentiment: The merger and reported Nasdaq delisting raise uncertainty for investors holding SUPN: the shares may no longer trade as a standalone Nasdaq-listed security, limiting the relevance of older SUPN targets and comparisons. Changes after Supernus’s Nasdaq delisting and merger

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for disorders of the central nervous system. The company’s activities center on epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on products designed to provide differentiated dosing or delivery characteristics.

Supernus’ marketed products include Trokendi XR (topiramate extended-release) for the prevention of migraine headaches and the treatment of certain seizure disorders, Oxtellar XR (oxcarbazepine extended-release) for partial-onset seizures, and Qelbree (viloxazine extended-release) for ADHD in patients six years of age and older.